蔡晓青，博士，教授，博士生导师；2011年在美国亚利桑那州立大学获博士学位；2011至2015年在美国Scripps研究所从事博士后研究；2016年通过中山大学“百人计划二期”人才引进回国工作，任职中山大学药学院，从事化学生物学和生物技术药物的相关研究。长期致力于蛋白质工程和抗体偶联技术的研究，针对蛋白质的胞内转运途径和降解等关键科学问题，聚焦抗体和抗体偶联药物 (ADC) 的研究。担任Frontiers in Molecular Bioscience特刊客座副主编。作为第一作者及通信作者在国际著名刊物J. Am. Chem. Soc., Chem. Sci., J. Med. Chem.等发表学术论文多篇。申请获得国家和国际专利多项。主持多项国家级、省级、校级基金项目以及横向课题项目。 教育经历 2006年8月－2011年7月：博士，美国亚利桑那州立大学 2004年9月－2006年7月：硕士，浙江大学 2000年9月－2004年7月：学士，浙江大学 工作经历 2025年3月－至今：教授，中山大学药学院 2016年9月－2025年3月：副教授，中山大学药学院 2011年8月－2015年6月：博士后，美国Scripps研究所

构建溶酶体靶向型的抗体偶联药物 (ADC)，从分子水平上干预和调控ADC的内吞和胞内转运途径，实现增强ADC的抗肿瘤活性、拓宽ADC的肿瘤适应症。 利用溶酶体的降解途径，发展靶向蛋白质降解技术，降解疾病相关的细胞膜蛋白，实现“不可成药”靶标的功能干预。 通过遗传密码扩增技术，利用含有特殊活性基团的非天然氨基酸对蛋白质进行定点修饰，发展基于非天然氨基酸的蛋白质修饰和标记技术，实现蛋白功能和活性的改造和升级

T. Fang, Z. Zheng, N. Li, Y. Zhang, J. Ma, C. Yun, Xiaoqing Cai*. Lysosome-targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins, Chemical Science, 15, 17652, 2024. C. Yun, N. Li, Y. Zhang, T. Fang, J. Ma, Z. Zheng, Xiaoqing Cai*. Glucose transporter-targeting chimeras enabling tumor-selective degradation of secreted and membrane proteins, ACS Chemical Biology, 19, 2254-2263, 2024. N. Li, S. Chen*, Xiaoqing Cai*. Harnessing molecular probes for imaging of human epidermal growth factor receptor (HER) family, Bioorganic & Medicinal Chemistry, 113, 117931, 2024. Z. Shi, X. Liu, S. Wu, N. Song, Q. Tang, H. Li, S. Luo, A. S. C. Chan, Xiaoqing Cai*; Liu, H.*, Jiang, X.* Discovery of novel peptide antagonists targeting GPR55 for liver inflammation and fibrosis, Journal of Medicinal Chemistry, 67, 12085-12098, 2024. J. Yu, H. Li, T. Fang, C. Yun, X. Liu, J. Xu, X. Jiang*, Xiaoqing Cai*. Harnessing the lysosomal sorting signals of the cation-independent mannose-6-phosphate receptor for targeted degradation of membrane proteins, Journal of the American Chemical Society, 145, 19107–19119, 2023. N. Song, H. Li, Q. Tang, S. Luo, Z. She, Q. Zhao, R. Li, Y. Chen, Xiaoqing Cai*, X. Jiang*, Design and discovery of novel cyclic peptides as EDPs-EBP interaction inhibitors for the treatment of liver fibrosis,Journal of Medicinal Chemistry, 66, 4689–4702, 2023. J. Yu, L. Gan, Y. Zhou, J. Xu, C. Yun, T. Fang, Xiaoqing Cai*, Indole-based long-wavelength fluorescent probes for bioimaging of S-nitrosylation in mitochondria, Chemistry-A European Journal, e202201494, 2022. J. Liu, Y. Chen, Xiaoqing Cai*, Research advances in new technologies in targeted protein degradation, Acta Pharmacologica Sinica., 57, 313-320, 2022. J. Yu, T. Fang, C. Yun, X. Liu, Xiaoqing Cai*, Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers, Frontiers in Molecular Biosciences., 9, 847835, 2022. Y. Cheng, J. Wu, Y. Han, J. Xu, Y. Da, Q. Zhao, G. Guo, Y. Zhou, Y. Chen, J. Liu, H. Chen, X. Jiang, Xiaoqing Cai*, A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease, Bioorganic & Medicinal Chemistry, 42, 116219, 2021. Q. Zhao, G. Guo, W. Zhu, Y. Da, H. Xu, S. Wu, Y. Cheng, Y. Zhou, Xiaoqing Cai*, X. Jiang*, Suzuki cross-coupling reaction with genetically encoded fluorosulfates for fluorogenic protein labeling, Chemistry-A European Journal, 26, 15938–15943, 2020. Y. Han, Y. Da, M. Yu, Y. Cheng, X. Wang, J. Xiong, G. Guo, Y. Li, X. Jiang, Xiaoqing Cai*, Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates, Organic & Biomolecular Chemistry, 18, 3229–3233, 2020. Z. Liu, X. Feng, J. Xu, X. Jiang, Xiaoqing Cai*, Construction of allylic amino acid derivatives through a catalytic asymmetric allylic alkylation of azlactones with vinyl cyclopropanes, Tetrahedron Letters, 61, 151694, 2020. H. Xu, L. Gan, Y. Han, Y. Da, J. Xiong, S. Hong, Q. Zhao, N. Song, Xiaoqing Cai*, X. Jiang, Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process, RSC Advances, 9, 1909–1917, 2019. N. Chen, L. Zhu, L. Gan, Z. Liu, R. Wang, Xiaoqing Cai*, X. Jiang, Asymmetric synthesis of bispiro[r-butyrolactone-pyrrolidin-4,4'-pyrozolone] scaffolds containing two quarternary spirocenters via an organocatalytic 1,3-dipolar cycloaddition, European Journal of Organic Chemistry, 2939–2943, 2018. Xiaoqing Cai, K. D. Janda*, A chemoenzymatic approach toward the preparation of site-specific antibody-drug conjugates, Tetrahedron Letters, 56, 3172–3175, 2015. Xiaoqing Cai, K. Tsuchikama, K. D. Janda*, Modulating anti-cocaine vaccine potency through hapten fluorination, Journal of the American Chemical Society, 135, 2971–2974, 2013. Xiaoqing Cai, T. Whitfield, M. S. Hixon, Y. Grant, G. F. Koob, K. D. Janda*, Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design, Journal of Medicinal Chemistry, 56, 3701–3709, 2013. Xiaoqing Cai, T. Whitfield, A. Y. Moreno, Y. Grant, M. S. Hixon, G. F. Koob, K. D. Janda*, Probing the effects of hapten stability on cocaine vaccine immunogenicity, Molecular Pharmacology, 10, 4176–4184, 2013. Xiaoqing Cai, O. M. Khdour, J. Jaruvangsanti, S. M. Hecht*, Simplified bicyclic pyridinol analogues protect mitochondrial function, Bioorganic & Medicinal Chemistry, 20, 3584–3595, 2012. Xiaoqing Cai, P. Zaleski, A. Cagir, S. M. Hecht*, Deglycobleomycin A6 analogues modified in the methylvalerate moiety, Bioorganic & Medicinal Chemistry, 19, 3831–3844, 2011.